Ionis Pharmaceuticals

Youtube Subscribe

Open: 39.92 Close: 39.55 Change: -0.37

You'll be sorry if you don't use an AI to decide whether to invest in Ionis Pharmaceuticals Stock.

Are looking for the most relevant information about Ionis Pharmaceuticals? Investor spend a lot of time searching for information to make investment decisions in Ionis Pharmaceuticals. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Ionis Pharmaceuticals are: Ionis, Pharmaceuticals, share, report, issue, EPS, estimate, and the most common words in the summary are: pharmaceutical, ionis, stock, inc, market, company, report, . One of the sentences in the summary was: Banque Cantonale Vaudoise lifted its holdings in shares of Ionis.. Other …

Concept Map

Semantic Network

Stock Summary

SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin am.

Today's Summary

William Blair cut their Q3 2023 EPS estimates for shares of IONS Pharmaceuticals in a report issued Wednesday. Banque Cantonale Vaudoise lifted its holdings in shares of Ionis.

Today's News

StockNews.com started coverage on shares of Ionis Pharmaceuticals (NASDAQ:IONS) in a research report issued on Thursday. William Blair cut their Q3 2023 EPS estimates for shares of IONS Pharmaceuticals in a report issued Wednesday. Leerink Partnrs has also provided estimates for Ionis Pharmaceuticals fourth-quarter 2023 earnings at ($1.21) EPS, as well as full-year earnings projections for fiscal years 2023-2027. Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. Banque Cantonale Vaudoise lifted its holdings in shares of Ionis. Pharmaceuticals to hold second quarter 2020 financial results webcast PRNewsWire. GlobalData tracks drug-specific phase transition and likelihood of approval scores. eplontersen sodium by ionis pharmaceuticals for familial amyloid cardiomyopathy: likelihood of. approval. Ionis Pharmaceuticals posted revenues of $188 million for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 37.39% Ionis shares have added about 4.7% since the beginning of the year versus the S&P 500s gain of 17.2%.

Stock Profile

"Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops Cimdelirsen to inhibit the production of growth hormone receptor; IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. Ionis Pharmaceuticals, Inc. was incorporated in 1989 and is based in Carlsbad, California."

Keywords

This document will help you to evaluate Ionis Pharmaceuticals without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Ionis Pharmaceuticals are: Ionis, Pharmaceuticals, share, report, issue, EPS, estimate, and the most common words in the summary are: pharmaceutical, ionis, stock, inc, market, company, report, . One of the sentences in the summary was: Banque Cantonale Vaudoise lifted its holdings in shares of Ionis.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #pharmaceutical #ionis #stock #inc #market #company #report.

Read more →

Youtube Subscribe

---